MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next- generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Forward-Looking Statements Media Contact [email protected] Mr. Pagano is currently Chief Financial Officer and Executive Vice President ...

Core Viewpoint - BillionToOne, Inc. reported strong financial results for Q3 2025, highlighting significant growth in revenue driven by its innovative molecular diagnostics technology, particularly in prenatal and oncology testing [3][5]. Financial Performance - Total revenue for Q3 2025 was $83.5 million, a 117% increase from $38.4 million in Q3 2024 [5][7]. - Prenatal clinical testing revenue reached $74.1 million, up 102% year-over-year, while oncology clinical testing revenue surged to $8.7 million, reflecting a 664% increase [5][7]. - Gross margin improved to 70% in Q3 2025 from 53% in Q3 2024, driven by higher average selling prices (ASP) and reduced costs per test [5][8]. - Operating income was $9.6 million in Q3 2025, compared to an operating loss of $12.6 million in Q3 2024 [9]. Test Volume and ASP - The company accessioned 162,900 tests in Q3 2025, a 51% increase from 107,900 tests in Q3 2024 [4][5]. - The overall ASP increased by 44% to $501 in Q3 2025 compared to $348 in Q3 2024 [6][7]. Cash Flow and IPO - Positive cash flow of $6.2 million was reported in Q3 2025 [5]. - The company raised gross proceeds of $314.0 million from its initial public offering (IPO) [10]. Future Guidance - BillionToOne expects full-year 2025 revenue to be between $293 million and $299 million, indicating growth of 92% to 96% compared to 2024 [11]. - The anticipated revenue for Q4 2025 is projected to be between $84 million and $90 million, representing an 86% to 100% increase year-over-year [11].

Core Viewpoint - BillionToOne, Inc. is set to release its financial results for the third quarter ending September 30, 2025, on December 9, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day [1] - A live and archived webcast of the conference call will be available on the company's investor relations website [2] Group 2: Company Overview - BillionToOne is headquartered in Menlo Park, California, and focuses on molecular diagnostics [3] - The company aims to create powerful and accurate tests that are accessible to all [3] - BillionToOne's patented Quantitative Counting Templates™ (QCT™) platform is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [3]

BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. The company, a commercial-stage molecular diagnostics company, offers specialized tests in prenatal genetics and oncology.Its patented Quantitative Counting Templates (QCT) platform uses multiplex technology to count DNA molecules at the single-molecule level.How Analysts Reacted “There is strong appetite for high-growth, profitable diagnostic com ...

Core Viewpoint - Several financial institutions have initiated coverage on various companies with positive ratings, indicating strong potential for growth and investment opportunities in their respective markets [1] Group 1: Company Initiations - UBS initiated coverage of Carvana (CVNA) with a Buy rating and a price target of $450, highlighting its "differentiated, best-in-class" online platform and customer experience, which positions it well in the large used vehicle market [1] - Benchmark initiated coverage of Cal-Maine Foods (CALM) with a Buy rating and a price target of $100, suggesting that the company's valuation is undervalued due to its legacy as a commodity producer, despite significant changes in the egg category and a shift towards more valuable specialty production [1] - Goldman Sachs initiated coverage of Beta Technologies (BETA) with a Buy rating and a price target of $47, viewing it as the best positioned among electric vertical take-off and landing companies, with multiple other firms also starting coverage with Buy-equivalent ratings [1] - JPMorgan initiated coverage of BillionToOne (BLLN) with an Overweight rating and a price target of $150, noting the company's potential to build its commercial infrastructure to meet growing demand in prenatal and oncology sectors, with several other firms also starting coverage with Buy-equivalent ratings [1] - Morgan Stanley initiated coverage of Evommune (EVMN) with an Overweight rating and a price target of $36, seeing favorable risk/reward for the shares despite early-stage data for its products, with other firms also starting coverage with Buy-equivalent ratings [1]

Core Viewpoint - Wall Street analysts have initiated coverage of BillionToOne following its recent Nasdaq debut, expressing positive sentiments regarding the company's advanced technology in diagnostics [1] Group 1: Company Overview - BillionToOne is a diagnostics firm that recently went public on Nasdaq, attracting attention from analysts who acted as lead underwriters during its debut [1] Group 2: Analyst Sentiment - Analysts have provided broadly upbeat views on BillionToOne, highlighting the potential of its advanced technology in the diagnostics sector [1]

Core Insights - BillionToOne (BLLN) has been trading for 14 days since its IPO on November 6, indicating a relatively new entry into the market [1] - The stock has established a base with a buy point at 123.84, as per IBD MarketSurge chart analysis tools [1] - Shares broke out on Monday and are currently in a 5% buy zone, which extends up to 130.03 [1] Investment Resources - IBD offers a trial for instant access to exclusive stock lists, expert market analysis, and powerful tools for a limited time [1] - The platform provides market updates, educational videos, webinars, and stock analysis to assist investors [1] - IBD's investing tools and top-performing stock lists aim to enhance investment strategies and profitability [1]

Core Points - BillionToOne, Inc. successfully closed its upsized initial public offering (IPO) of 5,233,765 shares of Class A common stock at a public offering price of $60.00 per share, resulting in gross proceeds of approximately $314.0 million before deductions [1] - The IPO included the full exercise of the underwriters' option to purchase an additional 682,665 shares [1] - The company's Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025 [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4] Offering Details - The registration statement related to the securities was filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025 [2] - A prospectus describing the terms of the offering has been filed with the SEC and is available on their website [2]

Core Viewpoint - Shares of BillionToOne (BLLN) have doubled on their opening day of trading, indicating strong investor optimism regarding the company's innovative technology for disease detection from a single drop of blood [1] Group 1: Company Overview - BillionToOne has developed a revolutionary technology aimed at detecting diseases, which has garnered significant attention from investors [1] Group 2: Market Reaction - The stock price of BillionToOne experienced a doubling on its first trading day, reflecting a positive market sentiment and high expectations for the company's future prospects [1]

Core Insights - Three companies, Evommune, BillionToOne, and Grupo Aeroméxico, went public on November 6, raising a total of $646 million, averaging approximately $215 million per company [1] Group 1: Evommune (EVMN) - Evommune opened at $17.25, a 7.25% increase from the offering price, and closed at $20.23, marking a 26.44% rise with a total market capitalization of $608 million [2][5] - The company issued 9.38 million shares at an offering price of $16, raising $150 million [5] - Evommune focuses on innovative therapies for immune-mediated inflammatory mechanisms, projecting $3 million in revenue and a net loss of $28.12 million for the first half of 2025 [5] Group 2: BillionToOne (BLLN) - BillionToOne opened at $100, a 66.67% increase from the offering price, and closed at $108.94, reflecting an 81.57% gain with a total market capitalization of $4.795 billion [6][9] - The company issued 4.55 million shares at an offering price of $60, raising $273 million [9] - BillionToOne specializes in molecular diagnostics, developing prenatal and oncology diagnostic products through its single-molecule next-generation sequencing (smNGS) platform, with projected revenue of $126 million and a net loss of $4.23 million for the first half of 2025 [9] Group 3: Grupo Aeroméxico (AERO) - Grupo Aeroméxico opened at $19.16, a slight increase of 0.84%, and closed at $20.35, resulting in a 7.11% rise with a total market capitalization of $2.969 billion [9][11] - The company issued 11.73 million shares at an offering price of $19, raising $223 million [11] - Grupo Aeroméxico provides domestic and international flight services, covering 22 countries and 52 international cities, with projected revenue of $2.498 billion and a net profit of $89.97 million for the first half of 2025 [11]